Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00726882 · ClinicalTrials.gov registry record · Phase 2
A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies
A Phase 2 study of HCV Infection, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 7
- Study locations
NCT00726882 is a Phase 2 study of HCV Infection that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 35 participants. The trial reports 7 study locations across 5 states.
The verdict
NCT00726882, a Phase 2 study of HCV Infection, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this follow-up study is to evaluate the frequency and persistence of specific viral mutations in response to treatment with ABT-333 (dasabuvir).
Conditions Studied
Interventions
- PROCEDURE Blood sample collection only
- DRUG ABT-333
Study Locations (7)
California
- Site Reference ID/Investigator# 17665 - Anaheim
- Site Reference ID/Investigator# 17367 - Los Angeles
- Site Reference ID/Investigator# 17672 - Los Angeles
Florida
- Site Reference ID/Investigator# 10381 - Orlando
Louisiana
- Site Reference ID/Investigator# 17667 - Baton Rouge
Texas
- Site Reference ID/Investigator# 14461 - San Antonio
Other
- Site Reference ID/Investigator# 11141 - Santurce
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00726882
The ClinicalTrials.gov registry entry for NCT00726882 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HCV Infection appearing as the primary indexed condition, and to 2 interventions - of which Blood sample collection only is the first listed.
NCT00726882 reports 7 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT00726882 about?
NCT00726882 is a clinical study titled "A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies". The purpose of this follow-up study is to evaluate the frequency and persistence of specific viral mutations in response to treatment with ABT-333 (dasabuvir).
What is the current status of trial NCT00726882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2008-08. Estimated completion is 2010-05.
What conditions does trial NCT00726882 study?
This clinical trial studies the following conditions: HCV Infection.
What interventions are being tested in trial NCT00726882?
The interventions under investigation include: Blood sample collection only (PROCEDURE), ABT-333 (DRUG).
Who is sponsoring clinical trial NCT00726882?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00726882 being conducted?
This trial has 7 study locations across California, Florida, Louisiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HCV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.